ABCL Stock On Track For Best Day In Nearly 4.5 Years After Positive Phase 2 Menopause Drug Data

• The study also showed significant improvements in sleep and patients’ overall perception of improvement.
• ABCL635 was well tolerated, with no serious or severe adverse events or treatment discontinuations reported.
• AbCellera ended Q2 with more than $565 million in cash and marketable securities and over $675 million in total available liquidity.

Shares of AbCellera (ABCL) surged more than 25% in pre-market trading on Monday, after the biotech firm reported positive topline Phase 2 results for ABCL635, its experimental non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) caused by menopause.

The study met its primary endpoints, with a single dose of ABCL635 significantly reducing both the frequency and severity of hot flashes after four weeks compared with placebo. Patients receiving ABCL635 saw an 83% reduction in hot flash frequency, versus 33% for placebo.

The study also showed significant improvements in sleep and patients’ overall perception of improvement. ABCL635 was well tolerated, with no serious or severe adverse events or treatment discontinuations reported.

ABCL stock is on track for its biggest single-day gains since March 2021, after having gained in nine of the past 10 sessions and adding about 32% to its value. So far this year, the shares have rallied over 100%. 

Why ABCL635 Is Important For AbCellera’s Pipeline

AbCellera’s ABCL635 is a potential first-in-class, non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes and night sweats.

The drug targets NK3R, a receptor involved in regulating body temperature. ABCL635 entered clinical development in July 2025 and is the first program from AbCellera’s GPCR and ion channel platform to reach the clinic. GPCRs and ion channels are proteins on or in cells that help control how cells communicate and respond to signals.

The company is evaluating the drug as a potential non-hormonal treatment for menopausal symptoms.

Cash Position Remains Strong Despite Q2 Miss

While the biotech firm missed its second-quarter revenue and earnings estimates last week, it ended the second quarter with more than $565 million in cash and marketable securities and over $675 million in total available liquidity.

Revenue came in at $4.1 million, well below Wall Street’s $7.9 million estimate, while its $0.18-per-share loss was slightly wider than the $0.17 per share expected loss.

Last quarter, AbCellera also announced a collaboration with Jazz Pharmaceuticals to develop T-cell engagers for gastrointestinal and other solid tumors, receiving $84 million in upfront payments.

ABCL Bulls Are Betting On A Breakout

Retail sentiment surrounding ABCL on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.

One user expects the stock to climb to $15, a 100% upside from current levels, if it breaks $8.

Another user highlighted the key data to look out for from the readout.

The stock has gained more than 102% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.